SSA
CNTA

Schonfeld Strategic Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.83M Buy
+171,933
New +$4.4M 0.05% 401
2025
Q4 		– Sell
-172,696
Closed -$4.19M – 2121
2025
Q3 		$4.19M Buy
172,696
+54,533
+46% +$969K 0.02% 665
2025
Q2 		$1.55M Sell
118,163
-159,407
-57% -$2.02M 0.01% 1109
2025
Q1 		$3.99M Sell
277,570
-87,630
-24% -$1.43M 0.02% 613
2024
Q4 		$6.12M Buy
+365,200
New +$6.05M 0.04% 433
2024
Q3 		– Sell
-12,300
Closed -$111K – 2092
2024
Q2 		$111K Buy
+12,300
New +$117K ﹤0.01% 1878
2024
Q1 		– Sell
-12,629
Closed -$101K – 2114
2023
Q4 		$101K Buy
+12,629
New +$84.7K ﹤0.01% 1620

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Schonfeld Strategic Advisors's CNTA Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in Centessa Pharmaceuticals (CNTA) in Q1 2026: 171,933 shares worth $6.83M. The stake represents 0.05% of the portfolio and ranks #401 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in CNTA as recently as Q3 2025.

Schonfeld Strategic Advisors first reported a position in CNTA in Q4 2023 and has held it in 7 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Schonfeld Strategic Advisors held 171,933 shares of Centessa Pharmaceuticals worth $6.83M as of Q1 2026.
  • Centessa Pharmaceuticals was a new Schonfeld Strategic Advisors position in Q1 2026.
  • Centessa Pharmaceuticals made up 0.05% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #401 holding.
  • Schonfeld Strategic Advisors first reported a position in Centessa Pharmaceuticals in Q4 2023 and has held it in 7 quarters since.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.